Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.

John N Allan Ian W Flinn Tanya Siddiqi Paolo Ghia Constantine S Tam Thomas J Kipps Paul M Barr Anna Elinder Camburn Alessandra Tedeschi Xavier C Badoux Ryan Jacobs Bryone J Kuss Livio Trentin Cathy Zhou Anita Szoke Christopher Abbazio William G Wierda

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Deep, durable responses and sustained PFS seen with fixed-duration ibrutinib plus venetoclax are maintained in patients with high-risk genomic features, with similar PFS and OS to those without high-risk features.

Keyphrases

chronic lymphocytic leukemia
phase ii
clinical trial
open label
randomized controlled trial
gene expression
metabolic syndrome
weight loss
insulin resistance
phase iii
copy number
adipose tissue
genome wide
placebo controlled
study protocol